The U.S. FDA approved Regeneron’s Pasatru (garetosmab) on August 19 for adults with fibrodysplasia ossificans progressiva, marking a striking turn for a program whose mid-stage study was discontinued in 2020 after dosing was paused following five patient deaths. The approval
